南通大学学报（医学版）
南通大學學報（醫學版）
남통대학학보（의학판）
JOURNAL OF NANTONG UNIVERSITY(MEDICAL SCIENCES)
2014年
4期
282-285
,共4页
宫颈癌%紫杉醇%化学治疗%顺铂%卡铂
宮頸癌%紫杉醇%化學治療%順鉑%卡鉑
궁경암%자삼순%화학치료%순박%잡박
cervical cancer%paclitaxel%chemotherapy%cisplatin%carboplatin
目的：比较紫杉醇+顺铂(TP)与紫杉醇+卡铂(TC)治疗中晚期宫颈癌的疗效和不良反应。方法：回顾性分析2007年1月-2010年9月我院收治的Ⅱb~Ⅳa期93例宫颈癌患者资料，所有患者均为初次根治性放疗。根据化疗方案的不同分为两组，A组：紫杉醇+顺铂联合3周化疗方案44例；B组：紫杉醇+卡铂联合3周化疗方案49例。 A、B组均采用根治性放疗(体外放疗+腔内后装治疗)，每周放疗5次。治疗结束后比较两组疗效及不良反应发生的情况。结果：A组近期有效率为91%，B组近期有效率为94%，两组比较差异无统计学意义(P=0.704)。 A、B组3年总生存率分别为65.9%和61.2%，3年无进展生存率分别为52.3%和49.0%，3年局部复发率分别为13.6%和12.2%，3年远处转移率分别为34.1%和38.8%，分别比较差异均无统计学意义(P>0.05)。不良反应：消化道反应、肾功能损害、周围神经毒性和肌肉关节痛A组明显较B组重(P<0.05)。结论：TP与TC方案治疗中晚期宫颈癌的疗效相当，但TC方案不良反应明显减轻，更易被患者接受，特别适用于老年患者及对顺铂耐受性差的患者。
目的：比較紫杉醇+順鉑(TP)與紫杉醇+卡鉑(TC)治療中晚期宮頸癌的療效和不良反應。方法：迴顧性分析2007年1月-2010年9月我院收治的Ⅱb~Ⅳa期93例宮頸癌患者資料，所有患者均為初次根治性放療。根據化療方案的不同分為兩組，A組：紫杉醇+順鉑聯閤3週化療方案44例；B組：紫杉醇+卡鉑聯閤3週化療方案49例。 A、B組均採用根治性放療(體外放療+腔內後裝治療)，每週放療5次。治療結束後比較兩組療效及不良反應髮生的情況。結果：A組近期有效率為91%，B組近期有效率為94%，兩組比較差異無統計學意義(P=0.704)。 A、B組3年總生存率分彆為65.9%和61.2%，3年無進展生存率分彆為52.3%和49.0%，3年跼部複髮率分彆為13.6%和12.2%，3年遠處轉移率分彆為34.1%和38.8%，分彆比較差異均無統計學意義(P>0.05)。不良反應：消化道反應、腎功能損害、週圍神經毒性和肌肉關節痛A組明顯較B組重(P<0.05)。結論：TP與TC方案治療中晚期宮頸癌的療效相噹，但TC方案不良反應明顯減輕，更易被患者接受，特彆適用于老年患者及對順鉑耐受性差的患者。
목적：비교자삼순+순박(TP)여자삼순+잡박(TC)치료중만기궁경암적료효화불량반응。방법：회고성분석2007년1월-2010년9월아원수치적Ⅱb~Ⅳa기93례궁경암환자자료，소유환자균위초차근치성방료。근거화료방안적불동분위량조，A조：자삼순+순박연합3주화료방안44례；B조：자삼순+잡박연합3주화료방안49례。 A、B조균채용근치성방료(체외방료+강내후장치료)，매주방료5차。치료결속후비교량조료효급불량반응발생적정황。결과：A조근기유효솔위91%，B조근기유효솔위94%，량조비교차이무통계학의의(P=0.704)。 A、B조3년총생존솔분별위65.9%화61.2%，3년무진전생존솔분별위52.3%화49.0%，3년국부복발솔분별위13.6%화12.2%，3년원처전이솔분별위34.1%화38.8%，분별비교차이균무통계학의의(P>0.05)。불량반응：소화도반응、신공능손해、주위신경독성화기육관절통A조명현교B조중(P<0.05)。결론：TP여TC방안치료중만기궁경암적료효상당，단TC방안불량반응명현감경，경역피환자접수，특별괄용우노년환자급대순박내수성차적환자。
Objective:To compare the efficacy and toxicity of paclitaxel plus cisplatin and paclitaxel plus carboplatin in the treatment of advanced cervical cancer. Methods:Between January 2007 and September 2010,93 cervical cancer patients with stageⅡb toⅣa who received Initial radical radiotherapy in our hospital. All cases were divided into two groups according to different chemotherapy regimens,the group receiving paclitaxel plus cisplatin chemotherapy every three weeks (group A,n=44),the group receiving paclitaxel plus carboplatin chemotherapy every three weeks(group B,n=49),Group A and Group B all adopt radical radiotherapy (external radiotherapy plus intracavitary brachytherapy),five times a week. Situation of efficacy and toxicity occurred were compared after the end of treatment. Results: The response rate(CR+PR) in group A was 91% and in group B was 94%,in which there was no significant difference(P=0.704). The three-year overall survival and the three-year progression-free survival of group A and group B were respectively 65.9%vs 61.2%(P>0.05) and 52.3%vs 49.0%(P>0.05). There were also no statistically significant differences between group A and group B in the three-year local recurrence rate and three-year distant metastasis(13.6% vs 12.2%,34.1% vs 38.8%;all P>0.05). Gastrointestinal reaction,renal dysfunction, myalgia or arthralgia and Peripheral neurotoxicity in group A was exactly higher than those in group B(P<0.05). Conclusions:Both chemotherapy regimens had similar efficacy on advanced cervical cancer patients with stage Ⅱb toⅣa. But the toxicity was milder in patients with paclitaxel plus carboplatin than those with paclitaxel plus cisplatin ,paclitaxel plus carboplatin is easy to be accepted by patients, and is especially suitable for the elderly and the patients with low tolerance to cisplatin.
